Why Does One Scientist Seek Cures for T1D? Answer: Family
Reza Abdi, M.D., has a reason to care about type 1 diabetes research—he has a father and a brother with…
Breakthrough T1D Launches First Center of Excellence, Aiming to Accelerate Type 1 Diabetes Research
Breakthrough T1D today launched its first Center of Excellence, a new research and funding model aimed at accelerating leading type…
FDA Breakthrough Therapy Designation for Teplizumab—Based on the First Study to Delay the Onset of T1D for 2+ Years
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to teplizumab, an anti-CD3 monoclonal antibody, for the prevention…
ADA Scientific Sessions Recap—Day #4: Simi Ahmed, Ph.D.
The American Diabetes Association’s Scientific Sessions is almost coming to a close! Here is Simi Ahmed, Ph.D., head of the…
First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset
This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune…
Your Cancer is Gone; Type 1 Diabetes is Here
Immune therapy has transformed cancer care. In some cases, cancer is effectively cured in people with stage 4 disease. But…
Closer to Cure: Renewed Funding for Type 1 Diabetes UK Immunotherapy Consortium (T1D UK)
More than 400,000 people in the United Kingdom and 1.25 million Americans have type 1 diabetes (T1D), a disease for…
JDRF-Backed Start-Up Company to Accelerate Work Through Pfizer
AnTolRx, Inc., a private biotechnology company, has agreed to license its immune tolerance therapy for type 1 diabetes (T1D) to…
